Skip to main content
SpringerLink
Log in

S3-Leitlinie Diagnostik und Therapie des Endometriumkarzinoms

Anforderungen an die Pathologie

S3 guidelines on the diagnosis and treatment of carcinoma of the endometrium

Requirements for pathology

  • Schwerpunkt: Gynäkopathologie
  • Published:
Der Pathologe Aims and scope Submit manuscript

Zusammenfassung

Die vorliegende Übersicht fasst die relevanten Aspekte der S3-Leitlinie Endometriumkarzinom zusammen. Die Empfehlungen umfassen die Aufarbeitung und Befunderhebung bei Abrasionen und Präparaten der (radikalen) Hysterektomie sowie der Lymphonodektomien, einschließlich der Sentinel-Lymphknoten-Diagnostik. Die Leitlinie berücksichtigt neben praktischen Aspekten der Pathologie ebenso die klinischen Notwendigkeiten an die Histopathologie für eine optimale operative, strahlentherapeutische und adjuvante Therapie der Patientinnen. Karzinosarkome werde als besondere Variante dem Endometriumkarzinom zugeordnet. Erstmals wird ein Algorithmus zur Diagnostik des Lynch-Syndroms bei Patientinnen mit einem Endometriumkarzinoms definiert. Zusätzlich werden morphologische Prognosefaktoren zusammengefasst.

Abstract

The present article summarises the relevant aspects of the S3 guidelines on endometrioid carcinomas. The recommendations include the processing rules of fractional currettings as well as for hysterectomy specimens and lymph node resections (including sentinel lymph nodes). Besides practical aspects, the guidelines consider the needs of the clinicians for appropriate surgical and radiotherapeutic treatment of the patients. Carcinosarcomas are assigned to the endometrial carcinoma as a special variant. For the first time, an algorithmic approach for evaluation of the tumour tissue for Lynch syndrome is given. Prognostic factors based on morphologic findings are summarised.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Abu-Rustum NR, Zhou Q, Gomez JD, Alektiar KM, Hensley ML, Soslow RA, Levine DA, Chi DS, Barakat RR, Iasonos A (2010) A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. Gynecol Oncol 116(3):399–403

    Article  CAS  PubMed  Google Scholar 

  2. Ahmed QF, Gattoc L, Al-Wahab Z, Abdulfatah E, Ruterbusch JJ, Cote M, Bandyopadhyay S, Morris RT, Ali-Fehmi R (2015) Vanishing endometrial cancer in hysterectomy specimens: a myth or a fact. Am J Surg Pathol 39(2):221–226

    Article  PubMed  Google Scholar 

  3. Ali A, Black D, Soslow RA (2007) Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int J Gynecol Pathol 26:115–123

    Article  PubMed  Google Scholar 

  4. Altrabulsi B, Malpica A, Deavers MT, Bodurka DC, Broaddus R, Silva EG (2005) Undifferentiated carcinoma of the endometrium. Am J Surg Pathol 29(10):1316–1321

    Article  PubMed  Google Scholar 

  5. Argani P, Cimino-Mathews A (2014) Intraoperative frozen sections. Diagnostic pitfalls. demosMedical, New York, S 255–258

    Google Scholar 

  6. AWMF (2014) S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom. AWMF-Leitliniennummer 032/033OL. http://www.awmf.org/uploads/tx_szleitlinien/032-033OLl_S3_Zervixkarzinom_2014-10.pdf. Zugegriffen: 24. Okt. 2018

    Google Scholar 

  7. AWMF (2015) S2k-Leitlinie zur Diagnostik, Therapie und Nachsorge des Vulvakarzinoms und seiner Vorstufen. AWMF-Leitliniennummer 015/059. http://www.awmf.org/uploads/tx_szleitlinien/015-059l_S2k_Vulvakarzinom_und_Vorstufen_Diagnostik_Therapie_2016-03_1.pdf. Zugegriffen: 24. Okt. 2018

    Google Scholar 

  8. Bartosch C, Lopes MJ, Oliva E (2011) Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features. Adv Anat Pathol 18(6):415–437

    Article  PubMed  Google Scholar 

  9. Bendifallah S, Canlorbe G, Huguet F, Coutant C, Hudry D, Graesslin O, Raimond E, Touboul C, Collinet P, Bleu G, Daraï E, Ballester M (2014) A risk scoring system to determine recurrence in early-stage type 1 endometrial cancer: a French multicentre study. Ann Surg Oncol 21(13):4239–4245

    Article  PubMed  Google Scholar 

  10. Bendifallah S, Canlorbe G, Raimond E, Bazire L, Huguet F, Graesslin O, Rouzier R, Darai E, Ballester M (2013) An external validation study of nomograms designed to predict isolated loco-regional and distant endometrial cancer recurrences: how applicable are they? Br J Cancer 109(6):1498–1503

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Bernardini MQ, Gien LT, Lau S, Altman AD, Gilks B, Ferguson SE, Köbel M, Samouëlian V, Wesa M, Cameron A, Nelson G, Han G, Clarke B, Ho TC, Panzarella T, Atenafu EG, McAlpine JN (2016) Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). Gynecol Oncol 141(1):148–154

    Article  PubMed  Google Scholar 

  12. Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15(1):10–17

    Article  CAS  PubMed  Google Scholar 

  13. Bosse T, Peters EE, Creutzberg CL, Jürgenliemk-Schulz IM, Jobsen JJ, Mens JW, Lutgens LC, van der Steen-Banasik EM, Smit VT, Nout RA (2015) Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer—a pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer 51(13):1742–1750

    Article  PubMed  Google Scholar 

  14. Bubien V, Bonnet F, Brouste V, Hoppe S, Barouk-Simonet E, David A, Edery P, Bottani A, Layet V, Caron O, Gilbert-Dussardier B, Delnatte C, Dugast C, Fricker JP, Bonneau D, Sevenet N, Longy M, Caux F (2013) French Cowden Disease Network, High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet 50(4):255–263

    Article  CAS  PubMed  Google Scholar 

  15. Buchanan DD, Tan YY, Walsh MD, Clendenning M, Metcalf AM, Ferguson K, Arnold ST, Thompson BA, Lose FA, Parsons MT, Walters RJ, Pearson SA, Cummings M, Oehler MK, Blomfield PB, Quinn MA, Kirk JA, Stewart CJ, Obermair A, Young JP, Webb PM, Spurdle AB (2014) Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. J Clin Oncol 32(2):90–100

    Article  CAS  PubMed  Google Scholar 

  16. SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Villella J, Herzog T, Shahin AF, Society of Gynecologic Oncology Clinical Practice Committee (2014) Endmetrial cancer: a review and current management strategies: part I. Gynecol Oncol 134(2):385–392

    Article  Google Scholar 

  17. SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Herzog TJ, Shahin FA, Society of Gynecologic Oncology Clinical Practice Committee (2014) Endometrial cancer: a review and current management strategies: part II. Gynecol Oncol 134(2):393–402

    Article  Google Scholar 

  18. Burleigh A, Talhouk A, Gilks CB, McAlpine JN (2015) Clinical and pathological characterization of endometrial cancer in young women: identification of a cohort without classical risk factors. Gynecol Oncol 138(1):141–146

    Article  PubMed  Google Scholar 

  19. Cantrell LA, Blank SV, Duska LR (2015) Uterine carcinosarcoma: A review of the literature. Gynecol Oncol 137(3):581–588

    Article  PubMed  Google Scholar 

  20. CAP: College of American Pathologists (2015) Protocol for the Examination of Specimens From Patients With Carcinoma of the Ovary. http://www.cap.org/web/oracle/webcenter/portalapp/pages/search-results.jspx?searchTerms=hysterectomy+omentectomy+peritoneal+biopsies+specify&_adf.ctrl-state=263oqd8k1_21&_afrLoop=629838432981632. Zugegriffen: 24. Okt. 2018

    Google Scholar 

  21. Chattopadhyay S, Galaal KA, Patel A, Fisher A, Nayar A, Cross P, Naik R (2012) Tumour-free distance from serosa is a better prognostic indicator than depth of invasion and percentage myometrial invasion in endometrioid endometrial cancer. BJOG 119(10):1162–1170

    Article  CAS  PubMed  Google Scholar 

  22. Clarke BA, Cooper K (2012) Identifying Lynch syndrome in patients with endometrial carcinoma: shortcomings of morphologic and clinical schemas. Adv Anat Pathol 19(4):231–238

    Article  PubMed  Google Scholar 

  23. Clarke BA, Gilks CB (2010) Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. J Clin Pathol 63(5):410–415

    Article  PubMed  Google Scholar 

  24. Cole AJ, Quick CM (2013) Patterns of myoinvasion in endometrial adenocarcinoma: recognition and implications. Adv Anat Pathol 20(3):141–147

    Article  CAS  PubMed  Google Scholar 

  25. Colgan TJ, Hirschowitz L, Kim I, McCluggage WG (2014) Neuroendocrine tumours of the uterine cervix. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) WHO classification of tumours of female reporductive tract. IARC Press, Lyon, S 196–198

    Google Scholar 

  26. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C (2016) ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group.ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol 27(1):16–41

    Article  CAS  PubMed  Google Scholar 

  27. Cox Bauer CM, Greer DM, Kram JJ, Kamelle SA (2016) Tumor diameter as a predictor of lymphatic dissemination in endometrioid endometrial cancer. Gynecol Oncol 141(2):199–205

    Article  PubMed  Google Scholar 

  28. Creutzberg CL, van Stiphout RG, Nout RA, Lutgens LC, Jürgenliemk-Schulz IM, Jobsen JJ, Smit VT, Lambin P (2015) Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials. Int J Radiat Oncol Biol Phys 91(3):530–539

    Article  PubMed  Google Scholar 

  29. Denschlag D, Thiel FC, Ackermann S, Harter P, Juhasz-Boess I, Mallmann P, Strauss HG, Ulrich U, Horn LC, Schmidt D, Vordermark D, Vogl T, Reichardt P, Gaß P, Gebhardt M, Beckmann MW (2015) Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015). Geburtshilfe Frauenheilkd 75(10):1028–1042

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Egoavil C, Alenda C, Castillejo A, Paya A, Peiro G, Sánchez-Heras AB, Castillejo MI, Rojas E, Barberá VM, Cigüenza S, Lopez JA, Piñero O, Román MJ, Martínez-Escoriza JC, Guarinos C, Perez-Carbonell L, Aranda FI, Soto JL (2013) Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers. PLoS ONE 8(11):e79737

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Elshaikh MA, Al-Wahab Z, Mahdi H, Albuquerque K, Mahan M, Kehoe SM, Ali-Fehmi R, Rose PG, Munkarah AR (2015) Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study. Gynecol Oncol 136(2):235–239

    Article  PubMed  Google Scholar 

  32. Euscher E, Fox P, Bassett R, Al-Ghawi H, Ali-Fehmi R, Barbuto D, Djordjevic B, Frauenhoffer E, Kim I, Hong SR, Montiel D, Moschiano E, Roma A, Silva E, Malpica A (2013) The pattern of myometrial invasion as a predictor of lymph node metastasis or extrauterine disease in low-grade endometrial carcinoma. Am J Surg Pathol 37(11):1728–1736

    Article  PubMed  PubMed Central  Google Scholar 

  33. Ferguson SE, Aronson M, Pollett A, Eiriksson LR, Oza AM, Gallinger S, Lerner-Ellis J, Alvandi Z, Bernardini MQ, MacKay HJ, Mojtahedi G, Tone AA, Massey C, Clarke BA (2014) Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer 120(24):3932–3939

    Article  PubMed  Google Scholar 

  34. Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA (2007) Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol 31(11):1653–1661

    Article  PubMed  Google Scholar 

  35. Ferraioli D, Chopin N, Beurrier F, Carrabin N, Buenerd A, Mathevet P (2015) The incidence and clinical significance of the micrometastases in the sentinel lymph nodes during surgical staging for early endometrial cancer. Int J Gynecol Cancer 25(4):673–680

    Article  PubMed  Google Scholar 

  36. Fujii H, Yoshida M, Gong ZX, Matsumoto T, Hamano Y, Fukunaga M, Hruban RH, Gabrielson E, Shirai T (2000) Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res 60(1):114–120

    CAS  PubMed  Google Scholar 

  37. Galic V, Schiavone MB, Herzog TJ, Holcomb K, Lewin SN, Lu YS, Neugut AI, Hershman DL, Wright JD (2013) Prognostic significance of mucinous differentiation of endometrioid adenocarcinoma of the endometrium. Cancer Invest 31(7):500–504

    Article  PubMed  PubMed Central  Google Scholar 

  38. Geels YP, Pijnenborg JM, van den Berg-van Erp SH, Bulten J, Visscher DW, Dowdy SC, Massuger LF (2012) Endometrioid endometrial carcinoma with atrophic endometrium and poor prognosis. Obstet Gynecol 120(5):1124–1131

    PubMed  Google Scholar 

  39. Geels YP, Pijnenborg JM, van den Berg-van Erp SH, Snijders MP, Bulten J, Massuger LF (2013) Absolute depth of myometrial invasion in endometrial cancer is superior to the currently used cut-off value of 50. Gynecol Oncol 129(2):285–291

    Article  CAS  PubMed  Google Scholar 

  40. Geels YP, van der Putten LJ, van Tilborg AA, Lurkin I, Zwarthoff EC, Pijnenborg JM, van den Berg-van Erp SH, Snijders MP, Bulten J, Visscher DW, Dowdy SC, Massuger LF (2015) Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium. Gynecol Oncol 137(2):245–251

    Article  CAS  PubMed  Google Scholar 

  41. Gungorduk K, Ozdemir A, Ertas IE, Selcuk I, Solmaz U, Ozgu E, Mat E, Gokcu M, Karadeniz T, Akbay S, Sanci M, Meydanli MM, Ayaz D, Gungor T (2015) Is mucinous adenocarcinoma of the endometrium a risk factor for lymph node involvement? A multicenter case-control study. Int J Clin Oncol 20(4):782–789

    Article  CAS  PubMed  Google Scholar 

  42. Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D, Comeras I, La Jeunesse J, Nakagawa H, Westman JA, Prior TW, Clendenning M, Penzone P, Lombardi J, Dunn P, Cohn DE, Copeland L, Eaton L, Fowler J, Lewandowski G, Vaccarello L, Bell J, Reid G, de la Chapelle A (2006) Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66(15):7810–7817

    Article  CAS  PubMed  Google Scholar 

  43. Hampel H, Panescu J, Lockman J, Sotamaa K, Fix D, Comeras I, LaJeunesse J, Nakagawa H, Westman JA, Prior TW, Clendenning M, de la Chapelle A, Frankel W, Penzone P, Cohn DE, Copeland L, Eaton L, Fowler J, Lombardi J, Dunn P, Bell J, Reid G, Lewandowski G, Vaccarello L (2007) Comment on: screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 67(19):9603

    Article  CAS  PubMed  Google Scholar 

  44. Han G, Lim D, Leitao MM Jr, Abu-Rustum NR, Soslow RA (2014) Histological features associated with occult lymph node metastasis in FIGO clinical stage I, grade I endometrioid carcinoma. Histopathology 64(3):389–398

    Article  PubMed  Google Scholar 

  45. Hanley KZ, Fadare O, Fisher KE, Atkins KA, Mosunjac MB (2016) Clinical significance of positive pelvic washings in uterine papillary serous carcinoma confined to an endometrial polyp. Int J Gynecol Pathol 35(3):249–255

    Article  PubMed  Google Scholar 

  46. Hertel JD, Huettner PC, Pfeifer JD (2014) Lymphovascular space invasion in microcystic elongated and fragmented (MELF)-pattern well-differentiated endometrioid adenocarcinoma is associated with a higher rate of lymph node metastasis. Int J Gynecol Pathol 33(2):127–134

    Article  PubMed  Google Scholar 

  47. Hirschowitz L, Nucci M, Zaino RJ (2013) Problematic issues in the staging of endometrial, cervical and vulval carcinomas. Histopathology 62(1):176–202

    Article  PubMed  Google Scholar 

  48. Hoekstra AV, Kim RJ, Small W Jr, Rademaker AW, Helenowski IB, Singh DK, Schink JC, Lurain JR (2009) FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes. Gynecol Oncol 114(2):273–278

    Article  PubMed  Google Scholar 

  49. Horn LC, Beckmann MW, Follmann M, Koch MC, Mallmann P, Marnitz S, Schmidt D, German Cancer Society (2015) S3 guidelines on diagnostics and treatment of cervical cancer: Demands on pathology. Pathologe 36(6):585–593

    Article  PubMed  Google Scholar 

  50. Horn LC, Dallacker M, Bilek K (2009) Carcinosarcomas (malignant mixed Mullerian tumors) of the uterus. Morphology, pathogenetic aspects and prognostic factors. Pathologe 30(4):292–301

    Article  PubMed  Google Scholar 

  51. Horn LC, Mayr D, Brambs CE, Einenkel J, Sändig I, Schierle K (2016) Grading of gynecological tumors : current aspects. Pathologe 37(4):337–351

    Article  PubMed  Google Scholar 

  52. Horn LC, Schnurrbusch U, Bilek K, Hentschel B, Einenkel J (2004) Risk of progression in complex an atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer 14(2):348–353

    Article  PubMed  Google Scholar 

  53. Horn LC, Trost M, Bilek K (2010) Staging of endometrial carcinoma: aspects of ovarian and cervical involvement. Int J Gynecol Pathol 29(1):63–66

    Article  PubMed  Google Scholar 

  54. Huvila J, Talve L, Carpén O, Edqvist PH, Pontén F, Grénman S, Auranen A (2013) Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. Gynecol Oncol 130(3):463–469

    Article  CAS  PubMed  Google Scholar 

  55. Jongen V, Briët J, de Jong R, ten Hoor K, Boezen M, van der Zee A, Nijman H, Hollema H (2009) Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 112(3):537–542

    Article  CAS  PubMed  Google Scholar 

  56. Jorge S, Hou JY, Tergas AI, Burke WM, Huang Y, Hu JC, Ananth CV, Neugut AI, Hershman DL, Wright JD (2016) Magnitude of risk for nodal metastasis associated with lymphvascular space invasion for endometrial cancer. Gynecol Oncol 140(3):387–393

    Article  PubMed  PubMed Central  Google Scholar 

  57. Kalyanasundaram K, Ganesan R, Perunovic B, McCluggage WG (2010) Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis. Int J Surg Pathol 18(2):138–143

    Article  CAS  PubMed  Google Scholar 

  58. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, Wilson RK, Raphael BJ, Ding L (2013) Mutational landscape and significance across 12 major cancer types. Nature 502(7471):333–339

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Kim HJ, Kim TJ, Song T, Kim MK, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG (2012) Patterns of recurrence in endometrial cancer patients at risk of lymph node metastasis or recurrence according to extent of lymphadenectomy. Int J Gynecol Cancer 22(4):611–616

    Article  CAS  PubMed  Google Scholar 

  60. Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, Britton H, Kommoss F, Grevenkamp F, Karnezis A, Yang W, Lum A, Krämer B, Taran F, Staebler A, Lax S, Brucker SY, Huntsman DG, Gilks CB, McAlpine JN, Talhouk A (2018) Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol 29(5):1180–1188

    Article  CAS  PubMed  Google Scholar 

  61. Kommoss FK, Karnezis AN, Kommoss F, Talhouk A, Taran FA, Staebler A, Gilks CB, Huntsman DG, Krämer B, Brucker SY, McAlpine JN, Kommoss S (2018) L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br J Cancer 119(4):480–486

    Article  CAS  PubMed  Google Scholar 

  62. Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RB, Kuo KT, Nakayama K, Clarke B, Shaw P, Olvera N, Kurman RJ, Levine DA, Wang TL, Shih IeM (2012) Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst 104(19):1503–1513

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Kumar S, Bandyopadhyay S, Semaan A, Shah JP, Mahdi H, Morris R, Munkarah A, Ali-Fehmi R (2011) The role of frozen section in surgical staging of low risk endometrial cancer. PLoS ONE 6(9):e21912

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Kurman RJ, Kaminski PF, Norris HJ (1985) The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 56(2):403–412

    Article  CAS  PubMed  Google Scholar 

  65. Kyrgiou M, Chatterjee J, Lyus R, Amin T, Ghaem-Maghami S (2013) The role of cytology and other prognostic factors in endometrial cancer. J Obstet Gynaecol 33(7):729–734

    Article  CAS  PubMed  Google Scholar 

  66. Lacey JV Jr, Chia VM (2009) Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas 63(1):39–44

    Article  PubMed  Google Scholar 

  67. Leenen CH, van Lier MG, van Doorn HC, van Leerdam ME, Kooi SG, de Waard J, Hoedemaeker RF, van den Ouweland AM, Hulspas SM, Dubbink HJ, Kuipers EJ, Wagner A, Dinjens WN, Steyerberg EW (2012) Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years. Gynecol Oncol 125(2):414–420

    Article  CAS  PubMed  Google Scholar 

  68. Lopez-Garcia MA, Palacios J (2010) Pathologic and molecular features of uterine carcinosarcomas. Semin Diagn Pathol 27(4):274–286

    Article  PubMed  Google Scholar 

  69. Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen LM, Allen B, Conrad P, Terdiman J, Sun C, Daniels M, Burke T, Gershenson DM, Lynch H, Lynch P, Broaddus RR (2005) Gynecologic cancer as a “sentinel cancer” for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 105(3):569–574

    Article  PubMed  Google Scholar 

  70. Lu KH, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, White KG, Luthra R, Gershenson DM, Broaddus RR (2007) Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol 25(33):5158–5164

    Article  CAS  PubMed  Google Scholar 

  71. Mahdi H, Mester JL, Nizialek EA, Ngeow J, Michener C, Eng C (2015) Germline PTEN, SDHB-D, and KLLN Alterations in Endometrial Cancer Patients With Cowden and Cowden-Like Syndromes: An International, Multicenter, Prospective Study. Cancer 121(5):688–696

    Article  CAS  PubMed  Google Scholar 

  72. Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Muñoz J, Argüelles R, Machin P, Prat J (2001) Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 32(6):569–577

    Article  CAS  PubMed  Google Scholar 

  73. Mauland KK, Wik E, Salvesen HB (2014) Clinical value of DNA content assessment in endometrial cancer. Cytometry B Clin Cytom 86(3):154–163

    Article  PubMed  Google Scholar 

  74. McCluggage WG, Colgan T, Duggan M, Hacker NF, Mulvany N, Otis C, Wilkinson N, Zaino RJ, Hirschowitz L (2013) Data set for reporting of endometrial carcinomas: recommendations from the International Collaboration on Cancer Reporting (ICCR) between United Kingdom, United States, Canada, and Australasia. Int J Gynecol Pathol 32(1):45–65

    Article  PubMed  Google Scholar 

  75. McCluggage WG, Hirschowitz L, Wilson GE, Oliva E, Soslow RA, Zaino RJ (2011) Significant variation in the assessment of cervical involvement in endometrial carcinoma: an interobserver variation study. Am J Surg Pathol 35(2):289–294

    Article  PubMed  Google Scholar 

  76. McCluggage WG, Judge MJ, Clarke BA, Davidson B, Gilks CB, Hollema H, Ledermann JA, Matias-Guiu X, Mikami Y, Stewart CJ, Vang R, Hirschowitz L (2015) Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol 28(8):1101–1122

    Article  PubMed  Google Scholar 

  77. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30:230–236

    Article  PubMed  Google Scholar 

  78. Meng B, Hoang LN, McIntyre JB, Duggan MA, Nelson GS, Lee CH, Köbel M (2014) POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol Oncol 134(1):15–19

    Article  CAS  PubMed  Google Scholar 

  79. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E (2016) Endometrial cancer. Lancet 387(10023):1094–1108

    Article  PubMed  Google Scholar 

  80. Movahedi-Lankarani S, Gilks CB, Soslow R, Oliva E, Members of the Cancer Committee, College of American Pathologists Protocol for the Examination of Specimens from Patients with Carcinoma of the Endometrium. http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2011/Endometrium_11protocol.doc. Zugegriffen: 24. Okt. 2018

    Google Scholar 

  81. Nakao Y, Yamasaki F, Yokoyama M, Aihara S, Yasunaga M, Iwasaka T (2014) Minimal deviation endometrioid adenocarcinoma of the endometrium and its MRI findings. Eur J Gynaecol Oncol 35(2):185–187

    CAS  PubMed  Google Scholar 

  82. Orezzoli JP, Sioletic S, Olawaiye A, Oliva E, del Carmen MG (2009) Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion. Gynecol Oncol 113(3):316–323

    Article  PubMed  Google Scholar 

  83. Ozturk E, Dikensoy E, Balat O, Ugur MG, Aydin A (2012) Intraoperative frozen section is essential for assessment of myometrial invasion but not for histologic grade confirmation in endometrial cancer: a ten-year experience. Arch Gynecol Obstet 285(5):1415–1419

    Article  PubMed  Google Scholar 

  84. Pacaut C, Bourmaud A, Rivoirard R, Moriceau G, Guy JB, Collard O, Bosacki C, Jacquin JP, Levy A, Chauleur C, Magné N, Merrouche Y (2015) Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy. Am J Clin Oncol 38(3):272–277

    Article  CAS  PubMed  Google Scholar 

  85. Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105:103–104

    Article  PubMed  Google Scholar 

  86. Pocrnich CE, Ramalingam P, Euscher ED, Malpica A (2016) Neuroendocrine carcinoma of the endometrium: a clinicopathologic study of 25 cases. Am J Surg Pathol 40(5):577–586

    Article  PubMed  PubMed Central  Google Scholar 

  87. Pollom EL, Conklin CM, von Eyben R, Folkins AK, Kidd EA (2016) Nomogram to predict risk of lymph node metastases in patients with endometrioid endometrial cancer. Int J Gynecol Pathol 35(5):395–401

    Article  PubMed  Google Scholar 

  88. Pradhan M, Abeler VM, Danielsen HE, Sandstad B, Tropé CG, Kristensen GB, Risberg BÅ (2012) Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium. Ann Oncol 23(5):1178–1184

    Article  CAS  PubMed  Google Scholar 

  89. Quddus MR, Sung CJ, Zhang C, Lawrence WD (2010) Minor serous and clear cell components adversely affect prognosis in “mixed-type” endometrial carcinomas: a clinicopathologic study of 36 stage-I cases. Reprod Sci 17(7):673–678

    Article  PubMed  Google Scholar 

  90. Robboy SJ, Mutter GL, Shako-Levy R, Bean SM, Prat J, Bentley RC, Russel P (2009) Cutup—gross description and processing of specimens. In: Robboy SJ, Mutter GL, Prat J, Bentley RC, Russel P, Anderson MC (Hrsg) Robboy’s pathology of the female reproductive tract. Elsevier, Edinburgh, London, New York, Oxford, Philadelphia, St. Louis, Sydney, Toronto, S 979–991

    Chapter  Google Scholar 

  91. Roelofsen T, van Ham MA, Wiersma van Tilburg JM, Zomer SF, Bol M, Massuger LF, Bulten J (2012) Pure compared with mixed serous endometrial carcinoma: two different entities? Obstet Gynecol 120(6):1371–1381

    Article  PubMed  Google Scholar 

  92. Rauh-Hain JA, Vargas RJ, Clemmer J, Clark RM, Bradford LS, Growdon WB, Goodman A, Boruta DM 2nd, Schorge JO, del Carmen MG (2016) Mucinous Adenocarcinoma of the Endometrium Compared With Endometrioid Endometrial Cancer: A SEER Analysis. Am J Clin Oncol 39(1):43–48

    Article  CAS  PubMed  Google Scholar 

  93. Sakai K, Yamagami W, Susumu N, Nomura H, Kataoka F, Banno K, Tsuda H, Aoki D (2015) Pathological factors associated with omental metastases in endometrial cancer. Eur J Gynaecol Oncol 36(4):397–401

    CAS  PubMed  Google Scholar 

  94. SGO Society of Gynecologic Oncologists (2005) Clinical practice committee statement on prohpylactic salpingo-oophorectomy. Gynecol Oncol 98:179–181

    Article  Google Scholar 

  95. Shaw PA, Clarke BA (2016) Prophylactic gynecologic specimens from hereditary cancer carriers. Surg Pathol Clin 9(2):307–328

    Article  PubMed  Google Scholar 

  96. Shiozaki T, Tabata T, Yamada T, Yamamoto Y, Yamawaki T, Ikeda T (2014) Does positive peritoneal cytology not affect the prognosis for stage I uterine endometrial cancer?: the remaining controversy and review of the literature. Int J Gynecol Cancer 24(3):549–555

    Article  PubMed  Google Scholar 

  97. Sho T, Hachisuga T, Nguyen TT, Urabe R, Kurita T, Kagami S, Kawagoe T, Matsuura Y, Shimajiri S (2014) Expression of estrogen receptor-α as a prognostic factor in patients with uterine serous carcinoma. Int J Gynecol Cancer 24(1):102–106

    Article  PubMed  Google Scholar 

  98. Singh R (2014) Review literature on uterine carcinosarcoma. J Cancer Res Ther 10(3):461–468

    PubMed  Google Scholar 

  99. Soslow RA (2013) High-grade endometrial carcinomas—strategies for typing. Histopathology 62(1):89–110

    Article  PubMed  Google Scholar 

  100. Skala SL, Hagemann IS (2015) Optimal sampling of grossly normal omentum in staging of gynecologic malignancies. Int J Gynecol Pathol 34(3):281–287

    Article  PubMed  Google Scholar 

  101. Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C (2014) A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. Health Technol Assess 18(58):1–406

    Article  PubMed  PubMed Central  Google Scholar 

  102. Clair StCM, Eriksson AG, Ducie JA, Jewell EL, Alektiar KM, Hensley ML, Soslow RA, Abu-Rustum NR, Leitao MM Jr (2016) Low-volume lymph node metastasis discovered during sentinel lymph node mapping for endometrial carcinoma. Ann Surg Oncol 23(5):1653–1659

    Article  Google Scholar 

  103. Steiner E, Einenkel J, Schmidt D, Horn LC (2012) Prädiktive und prognostische Marker beim Endometriumkarzinom. Onkologe 18:853–865

    Article  Google Scholar 

  104. Stephan JM, Hansen J, Samuelson M, McDonald M, Chin Y, Bender D, Reyes HD, Button A, Goodheart MJ (2014) Intra-operative frozen section results reliably predict final pathology in endometrial cancer. Gynecol Oncol 133(3):499–505

    Article  PubMed  Google Scholar 

  105. Syed S, Reed N, Millan D (2015) Adequacy of cervical sampling in hysterectomy specimens for endometrial cancer. Ann Diagn Pathol 19(2):43–44

    Article  PubMed  Google Scholar 

  106. Takano M, Ochi H, Takei Y, Miyamoto M, Hasumi Y, Kaneta Y, Nakamura K, Kurosaki A, Satoh T, Fujiwara H, Nagao S, Furuya K, Yokota H, Ito K, Minegishi T, Yoshikawa H, Fujiwara K, Suzuki M (2013) Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)? Br J Cancer 109(7):1760–1765

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Talhouk A, Hoang LN, McConechy MK, Nakonechny Q, Leo J, Cheng A, Leung S, Yang W, Lum A, Köbel M, Lee CH, Soslow RA, Huntsman DG, Gilks CB, McAlpine JN (2016) Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. Gynecol Oncol 143(1):46–53

    Article  PubMed  PubMed Central  Google Scholar 

  108. Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN (2017) Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 123(5):802–813

    Article  CAS  PubMed  Google Scholar 

  109. Talhouk A, Derocher H, Schmidt P, Leung S, Milne K, Gilks B, Anglesio MS, Nelson BH, McAlpine JN (2018) Molecular subtype not immune response drives outcomes in endometrial carcinoma. Clin Cancer Res:6. https://doi.org/10.1158/1078-0432.CCR-18-3241

    Article  PubMed  Google Scholar 

  110. Tejerizo-García A, Jiménez-López JS, Muñoz-González JL, Bartolomé-Sotillos S, Marqueta-Marqués L, López-González G, Gómez JF (2013) Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients. Onco Targets Ther 9:1305–1313

    PubMed  Google Scholar 

  111. Todo Y, Kato H, Okamoto K, Minobe S, Yamashiro K, Sakuragi N (2016) Isolated tumor cells and micrometastases in regional lymph nodes in stage I to II endometrial cancer. J Gynecol Oncol 27(1):e1

    Article  PubMed  CAS  Google Scholar 

  112. Torres ML, Weaver AL, Kumar S, Uccella S, Famuyide AO, Cliby WA, Dowdy SC, Gostout BS, Mariani A (2012) Risk factors for developing endometrial cancer after benign endometrial sampling. Obstet Gynecol 120(5):998–1004

    PubMed  PubMed Central  Google Scholar 

  113. Touboul C, Bentivegna E, Uzan C, Gouy S, Pautier P, Lhommé C, Duvillard P, Haie-Meder C, Morice P (2013) Sentinel lymph node in endometrial cancer: a review. Curr Oncol Rep 15(6):559–565

    Article  PubMed  Google Scholar 

  114. Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, Higgins R, Zaino R, Mutter GL (2012) Society of gynecologic oncology clinical practice committee. Management of endometrial precancers. Obstet Gynecol 120(5):1160–1175

    PubMed  PubMed Central  Google Scholar 

  115. Turan T, Oguz E, Unlubilgin E, Tulunay G, Boran N, Demir OF, Kose MF (2013) Accuracy of frozen-section examination for myometrial invasion and grade in endometrial cancer. Eur J Obstet Gynecol Reprod Biol 167(1):90–95

    Article  PubMed  Google Scholar 

  116. Ulker V, Tunca A, Numanoglu C, Akbayir O, Akyol A, Erim A, Ongut C (2014) Should omentectomy be a part of surgical staging in patients with endometrioid adenocarcinoma of the uterine corpus? Gynecol Obstet Invest 77(1):58–63

    Article  CAS  PubMed  Google Scholar 

  117. Vargas R, Rauh-Hain JA, Clemmer J, Clark RM, Goodman A, Growdon WB, Schorge JO, Del Carmen MG, Horowitz NS, Boruta DM 2nd (2014) Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol 133(2):216–220

    Article  PubMed  Google Scholar 

  118. Vidal F, Rafii A (2013) Lymph node assessment in endometrial cancer: towards personalized medicine. Obstet Gynecol Int 2013:892465

    Article  PubMed  PubMed Central  Google Scholar 

  119. Williams JW, Hirschowitz L (2006) Assessment of uterine wall thickness and position of the vascular plexus in the deep myometrium: implications for the measurement of depth of myometrial invasion of endometrial carcinomas. Int J Gynecol Pathol 25(1):59–64

    Article  PubMed  Google Scholar 

  120. Wittekind C, Meyer HJ (2011) TNM-Klassifikation maligner Tumoren. Endometriumkarzinom. Wiley-Blackwell, Weinheim, S 198–202

    Google Scholar 

  121. Wright JD, Barrena Medel NI, Sehouli J, Fujiwara K, Herzog TJ (2012) Contemporary management of endometrial cancer. Lancet 379(9823):1352–1360

    Article  PubMed  Google Scholar 

  122. Zaino R, Carinelli SG, Ellenson LH, Rng C, Katabuchi H, Konishi I, Lax S, Matias-Giu X, Mutter GL, Peters WA, Sherman ME, Shih IM, Soslow R, Stewart CJR (2014) Epitehlail tumors and precursosr of the endometrium. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) WHO classification of tumours of female Reporductive tract. IARC Press, Lyon, S 125–135

    Google Scholar 

  123. Zaino RJ, Abendroth C, Yemelyanova A, Oliva E, Lim D, Soslow R, Delair D, Hagemann IS, Montone K, Zhu J (2013) Endocervical involvement in endometrial adenocarcinoma is not prognostically significant and the pathologic assessment of the pattern of involvement is not reproducible. Gynecol Oncol 128(1):83–87

    Article  PubMed  Google Scholar 

  124. Zaino RJ (2009) FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int J Gynecol Pathol 28:1–9

    Article  PubMed  Google Scholar 

  125. Zaino RJ (2014) Unusual patterns of endometrial carcinoma including MELF and its relation to epithelial mesenchymal transition. Int J Gynecol Pathol 33(4):357–364

    Article  CAS  PubMed  Google Scholar 

  126. Zannoni GF, Monterossi G, De Stefano I, Gargini A, Salerno MG, Farulla I, Travaglia D, Vellone VG, Scambia G, Gallo D (2013) The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer. Hum Pathol 44(6):1047–1054

    Article  CAS  PubMed  Google Scholar 

  127. Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M (2013) L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst 105(15):1142–1150

    Article  PubMed  Google Scholar 

  128. Zheng W, Schwartz PE (2005) Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management. Gynecol Oncol 96(3):579–582

    Article  PubMed  Google Scholar 

  129. Zhu J, Wen H, Bi R, Wu X (2016) Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study. J Gynecol Oncol 27(2):e18

    Article  PubMed  CAS  Google Scholar 

Download references

Mitglieder der Kommission zur Erstellung der S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom

Prof. Dr. Bernd Alt-Epping, Göttingen; Prof. Dr. Stefan Aretz, Bonn; PD Dr. Dr. Gerd Bauerschmitz, Göttingen; Prof. Dr. Matthias W. Beckmann, Erlangen; Dr. Nina Bock, Göttingen; Dr. Wolfgang Cremer, Hamburg; Dr. Timm Dauelsberg, Nordrach; Prof. Dr. Günter Emons, Göttingen; Prof. Dr. Petra Feyer, Berlin; Prof. Dr. Markus Fleisch, Wuppertal; Prof. Dr. Michael Friedrich, Krefeld; Marion Gebhardt, Forchheim; Prof. Dr. Dieter Grab, München; Dr. Volker Hagen, Dortmund; Prof. Dr. Volker Hanf, Fürth; Ulla Henscher, Hannover; Prof. Dr. Felix Hilpert, Hamburg; Prof. Dr. Stefan Höcht, Saarlouis; Prof. Dr. Lars-Christian Horn, Leipzig; Prof. Dr. Jutta Hübner, Jena; Prof. Dr. Ingolf Juhasz-Böss, Homburg; Prof. Dr. Ludwig Kiesel, Münster; Prof. Dr. Rainer Kimmig, Essen; Prof. Dr. Michael Kreißl, Magdeburg; PD Dr. Christian Kurzeder, Basel; Prof. Dr. Jan Langrehr, Berlin; Prof. Dr. Sigurd Lax, Graz; Prof. Dr. Steffen Leinung, Grimma; PD Dr. Anne Letsch, Berlin; Prof. Dr. Werner Lichtenegger, Berlin; Prof. Dr. Peter Mallmann, Köln; Prof. Dr. Doris Mayr, München; Prof. Dr. Alfons Meindl, München; Prof. Dr. Jan Menke, Göttingen; Prof. Dr. Michael D. Mueller, Bern; Prof. Dr. Alexander Mustea, Greifswald; Prof. Dr. Peter Niehoff, Offenbach; Dr. Christiane Niehues, Berlin; Prof. Dr. Birgitt van Oorschot, Würzburg; Prof. Dr. Olaf Ortmann, Regensburg; Dr. Joan Elisabeth Panke, Essen; Kerstin Paradies, Hamburg; Prof. Dr. Edgar Petru, Graz; Prof. Dr. Heinrich Prömpeler, Freiburg; Prof. Dr. Franz-Josef Prott, Wiesbaden; Dr. Nils Rahner, Düsseldorf; Prof. Dr. Michael J. Reinhardt, Oldenburg; Dr. Anne D. Rose, Berlin; Prof. Dr. Ingo Runnebaum, MBA; Prof. Dr. Rita Katharina Schmutzler, Köln; Annemarie Schorsch, Bad Soden; Prof. Dr. Eric Steiner, Rüsselsheim; Dr. Verena Steinke-Lange, München; Prof. Dr. Vratislav Strnad, Erlangen; Prof. Dr. Clemens Tempfer, MBA, Herne; Reina Tholen, Bremen/Köln; Dr. Christoph Uleer, Hildesheim; Prof. Dr. Dirk Vordermark, Halle; Prof. Dr. Joachim B. Weis, Freiburg; PD Dr. Edward Wight, Basel; Dr. Ralf Witteler, Münster; Prof. Dr. Alain-Gustave Zeimet, Innsbruck

Author information

Authors and Affiliations

  1. Abteilung Mamma‑, Gynäko- & Perinatalpathologie, Institut für Pathologie, Universitätsklinikum Leipzig AöR, Liebigstraße 24, 04103, Leipzig, Deutschland

    L.-C. Horn

  2. Frauenklinik, Universitätsmedizin Göttingen, Göttingen, Deutschland

    G. Emons & N. Bock

  3. Institut für Humangenetik, Universitätsklinikum Bonn, Bonn, Deutschland

    S. Aretz

  4. Deutsche Krebsgesellschaft, Berlin, Deutschland

    M. Follmann

  5. Institut für Pathologie, Landeskrankenhaus Graz West, Graz, Österreich

    S. Lax

  6. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Berlin, Deutschland

    M. Nothacker

  7. Frauenklinik, GPR Klinikum Rüsselsheim, Rüsselsheim, Deutschland

    E. Steiner

  8. Pathologisches Institut, Medizinische Fakultät, Ludwig-Maximilians-Universität München, München, Deutschland

    D. Mayr

Authors
  1. L.-C. Horn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Emons
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Aretz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Bock
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Follmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Lax
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Nothacker
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E. Steiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D. Mayr
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Deutsche Krebsgesellschaft (DKG)

Kommission zur Erstellung der S3-Leitlinie „Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom“

Corresponding author

Correspondence to L.-C. Horn.

Ethics declarations

Interessenkonflikt

L.-C. Horn, G. Emons, S. Aretz, N. Bock, M. Follmann, S. Lax, M. Nothacker, E. Steiner und D. Mayr geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

H. A. Baba, Essen

Der Inhalt des Beitrags entspricht dem Text der S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom. Die Mitglieder der Kommission zur Erstellung der genannten S3-Leitlinie werden am Beitragsende gelistet.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Horn, LC., Emons, G., Aretz, S. et al. S3-Leitlinie Diagnostik und Therapie des Endometriumkarzinoms. Pathologe 40, 21–35 (2019). https://doi.org/10.1007/s00292-019-0574-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00292-019-0574-7

Schlüsselwörter

Keywords

Search

Navigation